NCT00170885
Completed
Phase 4
Multicenter, Randomized, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of Two Regimens of Everolimus Plus Cyclosporine Microemulsion, Given According to Different Blood Target Levels, in de Novo Renal Transplant Recipients
ConditionsKidney Transplantation
DrugsEverolimus
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Kidney Transplantation
- Sponsor
- Novartis
- Locations
- 1
- Primary Endpoint
- Renal function assessed by glomerular filtration rate before and during the first 6 months of treatment
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of the study in de novo renal transplant patients is to evaluate the effect on renal function of an optimized new regimen in comparison with the standard everolimus exposure plus a low-dose cyclosporine microemulsion regimen.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Recipients of deceased, living unrelated, or non-human leukocyte antigen (HLA) identical living related donor renal transplant who actually have a viable kidney transplant at the time of randomization (within 24 hours of graft reperfusion)
- •The renal cold ischemic time must be \< 36 hours.
- •The age of the donor must be between 15 and 65 years.
Exclusion Criteria
- •Patients who are recipients of multiple organ transplants, including more than one kidney
- •Patients who have previously received an organ transplant which failed within one year
- •Patients with current panel reactive T-cell antibody titers of 50% or more
- •Patients who are recipients of A-B-O incompatible transplants or T-cell crossmatch positive transplant
- •Other protocol-defined exclusion criteria may apply.
Outcomes
Primary Outcomes
Renal function assessed by glomerular filtration rate before and during the first 6 months of treatment
Secondary Outcomes
- Metabolic control: lipids, glycaemic control, proteinuria, enzymes
- Ultrasound ejection fraction
- Major adverse cardiovascular events
- Pharmacokinetics (PK)
- Count of CD4 and CD8 positive lymphocytes
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant PatientsKidney TransplantationNCT00048152Hoffmann-La Roche539
Completed
Phase 3
Study Evaluating Sirolimus in Kidney Transplant RecipientsGraft vs Host DiseaseKidney TransplantationNCT00195273Wyeth is now a wholly owned subsidiary of Pfizer61
Not yet recruiting
Not Applicable
Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study.Diabetic Nephropathy Type 2NCT06222476Yan Bi106
Completed
Phase 4
A One-year, Open Label Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients.Kidney TransplantationNCT00154245Novartis20
Completed
Phase 3
Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal FunctionChronic Kidney DiseaseNCT02334488Poitiers University Hospital329